9Bio Therapeutics
9Bio Therapeutics is a Quebec City-based biotech that uses its AI-guided Ninera™ structural biology platform to engineer tumor-selective antibody-drug conjugates for oncology, serving pharmaceutical partners and patients with advanced solid tumors.
- Company typePrivate
- Founded2023
- HeadquartersQuebec, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What 9Bio Therapeutics does
9Bio Therapeutics is a privately held Canadian biotechnology company headquartered in Quebec City, founded in 2023, that develops next-generation tumor-selective cancer therapies using a proprietary AI-guided structural biology platform branded Ninera™. The platform integrates three computational engines — Ninera™ Discovery (large-scale variant exploration and condition-aware optimization), Ninera™ Dynamics (molecular dynamics simulation of binding behavior over time), and Ninera™ Glycans (in-development glycan-aware dynamic modeling) — to engineer biologics with disease-selective activity, notably pH-dependent tumor-selective anti-PD-L1 antibodies and bispecific constructs targeting peptide-MHC and tumor-associated antigens. Its internal pipeline comprises three discovery-stage antibody-drug conjugates: 9B02 (anti-PD-L1 ADC), 9B05 (bispecific ADC for metastatic colorectal, gastric, breast, and liver cancers), and 9B06 (next-generation bispecific ADC for advanced solid tumors).
The company operates a partnership- and licensing-driven business model intended to generate future revenue through out-licensing or co-development of pipeline assets with pharmaceutical partners, supplemented by platform technology service collaborations (e.g., Neomabs Biotechnologies, RivioBio, and Vega BioImaging). To date, 9Bio has been funded primarily through non-dilutive Canadian public grants (NRC-IRAP, NSERC, Quebec/CQDM Partenar-IA), strategic investment from the Merck Digital Sciences Studio with CQDM, in-kind cloud credits from Microsoft for Startups, and acceleration support from adMare BioInnovations. The company serves oncology-focused pharmaceutical and biotech partners and, ultimately, patients with advanced or metastatic solid tumors where conventional ADCs face on-target/off-tumor toxicity and chemotherapy resistance challenges.
9Bio Therapeutics firmographics
Firmographics- Name
- 9Bio Therapeutics
- Legal name
- 9Bio Therapeutics Inc.
- Website
- https://9biotx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- 9Bio Therapeutics is a Quebec City-based biotech that uses its AI-guided Ninera™ structural biology platform to engineer tumor-selective antibody-drug conjugates for oncology, serving pharmaceutical partners and patients with advanced solid tumors.
- Ownership category
- akta.pro rank
9Bio Therapeutics industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Bispecific & Multispecific Antibodies (HLAAAAAF), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where 9Bio Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Quebec
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
9Bio Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Therapeutic Development & Licensing: 9Bio develops proprietary therapeutic candidates through preclinical stages and seeks to out-license or co-develop with pharmaceutical partners. Revenue will be generated through licensing deals, milestone payments, and royalty streams from approved therapeutics.
- Platform Technology Partnerships: The company offers its computational protein engineering platform capabilities to external partners for collaborative drug development projects, including tumor-selective binding engineering and bispecific antibody development.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
9Bio Therapeutics product offering
Product offeringCore offering
9Bio Therapeutics develops next-generation tumor-selective cancer therapies using its proprietary Ninera™ computational protein engineering platform. The company builds conditionally active antibody-drug conjugates (ADCs) and bispecific antibodies designed to preferentially bind cancer cells in the tumor microenvironment, reducing off-tumor toxicity. Its pipeline includes 9B02 (anti-PD-L1 ADC), 9B05 (bispecific ADC for metastatic cancers), and 9B06 (next-generation bispecific ADC), with intended commercialization through licensing and co-development partnerships with pharmaceutical companies.
Product overview
9Bio Therapeutics is a biotech company that has developed a unified computational protein engineering platform called Ninera™ for engineering conditionally active biologics for oncology. The platform integrates three specialized engines: Ninera™ Discovery (for large-scale digital variant testing and optimization), Ninera™ Dynamics (for binding behavior analysis over time), and Ninera™ Glycans (for glycoprotein interaction modeling, in development). The company's therapeutic pipeline includes three ADC programs: 9B02 (anti-PD-L1 conditional ADC), 9B05 (bispecific ADC for metastatic cancers), and 9B06 (next-generation bispecific ADC). Beyond its platform, 9Bio offers service capabilities including antibody discovery, protein production/purification, antibody engineering, and candidate characterization through its collaboration network.
Differentiator
Problem solved
Functional benefit
Brands
- Ninera™: Computational protein engineering platform that integrates structural modeling, molecular dynamics, and in silico developability assessment to precisely control protein-protein interactions. Includes three engines: Ninera™ Discovery, Ninera™ Dynamics, and Ninera™ Glycans (in development).
Products and services
- Ninera™ Platform A computational protein engineering platform that integrates structural modeling, molecular dynamics simulation, and in silico developability assessment to precisely control protein-protein interactions for designing conditionally active biologics for oncology applications.
- 9B02 Anti-PD-L1 ADC A conditional, tumor-selective anti-PD-L1 antibody-drug conjugate designed to improve tumor selectivity and patient tolerability by preferentially binding PD-L1 within the tumor microenvironment, enabling direct elimination of tumor cells and immunosuppressive immune cells. Targets gastric and bladder cancers with broader potential in NSCLC, TNBC, HNC, and melanoma.
- 9B05 Bispecific ADC A bispecific antibody-drug conjugate for advanced metastatic cancers combining a clinically validated tumor antigen associated with cancer stemness and chemotherapy resistance with a novel tumor antigen for metastatic progression, targeting colorectal, gastric, and breast cancers including metastatic disease.
- 9B06 Next-Generation Bispecific ADC A next-generation bispecific ADC combining 9Bio's conditional tumor-selective anti-PD-L1 ADC platform with a complementary tumor-associated antigen, designed to improve tumor selectivity through avidity-driven binding for advanced and metastatic solid tumors.
- Antibody Discovery Services Complementary antibody discovery services including immunization and phage and yeast display approaches for identifying therapeutic antibody candidates, offered through 9Bio's collaboration network.
- Antibody Engineering Services Sequence and structure-based humanization, CDR optimization, bispecific and multispecific antibody engineering, and custom antibody fusion protein services for therapeutic development partners.
- Candidate Characterization Services Evaluation of binding, kinetics, epitope binning, developability, purity, stability, and cell-based functional assessment services for therapeutic antibody candidates.
- Protein Production and Purification Services Small-scale expression, purification, and preparation of antibody and protein candidates for downstream testing, delivered through 9Bio's collaboration network.
- Conditional Activity Engineering Engineering service for pH-dependent binding for tumor selectivity and multidimensional specificity for peptide-MHC targeting, enabling re-engineering of validated antibody frameworks into more selective therapeutic candidates.
Quantifiable outcome
- Engineered antibody demonstrated highly selective binding and potent tumor cell killing under disease-relevant acidic pH conditions while showing no detectable activity at physiological pH values
- +2 more outcomes
Companies that use 9Bio Therapeutics
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
9Bio Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature3 records
9Bio Therapeutics partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered major, core and minor.
- Microsoft for StartupsmajorHighest Azure credit tier providing $150,000 USD in cloud credits to support computational protein engineering platform development, including large-scale digital exploration of antibody variants, molecular modeling, and candidate optimization.
- Vega BioImagingcore$1.8M collaboration in targeted oncology therapies with $0.9M from Quebec government via Partenar-IA. 9Bio developing conditionally active ADC; Vega developing companion diagnostic kit. Each company retains full IP. Focus on head/neck and metastatic breast cancers.
- TransBIOTechmajor$450,000 ARD grant via NSERC CCI program. TransBIOTech (Cégep de Lévis) provides preclinical research expertise including functional immune assays, tumor cell killing studies, and in vivo pharmacokinetic studies. 9Bio retains full control over development and commercialization.
- Aramis BiotechnologiesminorPart of $2M collaborative initiative. Aramis will manufacture antibodies using its flexible plant-based production platform. Each company retains its own IP.
- Molecular ForecasterminorPart of $2M collaborative initiative. Molecular Forecaster uses biophysics-based approach with machine learning to generate small molecules targeting tumor cells. Each company retains its own IP.
- adMare BioInnovationscoreMembership in National Therapeutics (Tx) Accelerator providing scientific and business development guidance, IP/legal assistance, financial support, and access to professional network. adMare currently has 29 portfolio companies that have attracted $2.3B of risk capital.
- McGill UniversityminorAcademic partnership through advisors including Dr. Gerald Batist (Director of McGill Centre for Translational Research in Cancer), CEO Henrique de Carvalho's MBA alma mater, and collaborative research relationships.
- Université LavalminorAcademic partnership through advisor Dr. Sophie Gobeil (professor), Entrepreneuriat U Laval partnership, and IVADO consortium membership connecting multiple Quebec universities.
- Université de MontréalminorAcademic partner through IVADO consortium and advisor Dr. Martin Bonenfant's PhD alma mater. Core team member Jonathan Besna completing PhD at Université de Montréal.
- IVADOmajorInterdisciplinary AI research consortium providing $0.9M+ in grants through Partenar-IA program. Led by Université de Montréal with partners including Polytechnique Montréal, HEC Montréal, Université Laval, and McGill University.
- Roswell Park Comprehensive Cancer CenterminorAdvisory relationship through Dr. AJ Robert McGray, Assistant Professor of Oncology and Immunotherapy. Research collaboration on bispecific T cell engagers and anti-tumor immune responses.
- BioQuebecminorQuebec biotech industry association membership providing networking, advocacy, and ecosystem support for Quebec life sciences companies.
- Neomabs BiotechnologiesminorCollaboration using 9Bio's structure-guided approach to explore new strategies for improving therapeutic candidates and addressing complex protein engineering challenges.
- RivioBiominorContinued collaboration from previous biotech venture, applying scientific insight and creative thinking to strengthen drug development programs.
Scale indicators7 records
Recent moves6 records
Expansion highlights7 records
9Bio Therapeutics competitors and assessment
Company assessmentDirect peers
- AbCellera Biologics: Public AI-driven antibody discovery platform that partners with pharma to identify therapeutic antibodies using computational and high-throughput experimental screening. Highly comparable to 9Bio's Ninera™ antibody discovery and engineering capability, though AbCellera operates at much greater scale with a partnered pipeline model.
- BigHat Biosciences: AI/ML-driven antibody design platform combining wet-lab high-throughput characterization with computational design to engineer safer, more effective antibodies. Closely comparable to 9Bio's integrated computation-plus-laboratory workflow for selectivity engineering.
- Pyxis Oncology: Clinical-stage biotech developing antibody-drug conjugates and immunotherapies for difficult-to-treat cancers. Directly comparable therapeutic focus to 9Bio's ADC pipeline, though Pyxis is further advanced clinically.
- Generate Biomedicines: Generative AI platform that designs novel protein therapeutics de novo across multiple modalities including antibodies and multispecifics. Comparable to 9Bio's AI-guided structural biology approach to engineering biologics with desired selectivity profiles.
- Absci: Generative AI drug creation company building de novo antibodies and other biologics using zero-shot generative models. Direct competitor in the AI-designed antibody space, with a public-company platform model that parallels 9Bio's partner-driven strategy.
- Cradle Bio: AI protein engineering platform helping biotech and pharma partners design and optimize proteins including antibodies and enzymes. Comparable generative-protein-design positioning to 9Bio's Ninera™ platform.
Broad incumbents
- Mersana Therapeutics: Clinical-stage ADC developer with multiple platforms (Dolasynthen, Immunosynthen) and partnered programs. Comparable oncology-ADC focus and licensing strategy, though at significantly later stage and broader scale.
- Schrödinger: Public computational drug discovery company offering physics-based and ML software for molecular design, including biologics modeling. Broad incumbent in the computational protein engineering space where 9Bio's Ninera™ competes.
- Heidelberg Pharma: Germany-based ADC company with proprietary Amanitin-based payload platform and multiple clinical-stage ADC programs. Comparable ADC therapeutic focus, broader modality coverage, and partnership-driven licensing model.
Emerging players
- Insitro: Machine-learning-driven drug discovery company combining high-throughput biology with ML models to discover therapeutics, with growing focus on biologics. Comparable technology stack to 9Bio, though Insitro's pipeline skews more toward metabolic and neurological diseases than oncology ADCs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
9Bio Therapeutics social profiles
Digital presence9Bio Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
9Bio Therapeutics leadership team
Management profileNumber of profiles
Profiles14 records
9Bio Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
9Bio Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 9Bio Therapeutics
What does 9Bio Therapeutics do?
9Bio Therapeutics develops next-generation tumor-selective cancer therapies using its proprietary Ninera™ computational protein engineering platform. The company builds conditionally active antibody-drug conjugates (ADCs) and bispecific antibodies designed to preferentially bind cancer cells in the tumor microenvironment, reducing off-tumor toxicity. Its pipeline includes 9B02 (anti-PD-L1 ADC), 9B05 (bispecific ADC for metastatic cancers), and 9B06 (next-generation bispecific ADC), with intended commercialization through licensing and co-development partnerships with pharmaceutical companies.
Is 9Bio Therapeutics a public or private company?
9Bio Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was 9Bio Therapeutics founded?
9Bio Therapeutics was founded in 2023. It employs 1 to 10 people.
Where is 9Bio Therapeutics based?
9Bio Therapeutics is headquartered in Quebec, Canada, in the North America region.
How does 9Bio Therapeutics make money?
Two revenue lines are on record. Therapeutic Development & Licensing is the primary driver. The others are platform Technology Partnerships.
Who are 9Bio Therapeutics's main competitors?
Direct peers on record are AbCellera Biologics, BigHat Biosciences, Pyxis Oncology, Generate Biomedicines, Absci and Cradle Bio. Broad incumbents are Mersana Therapeutics, Schrödinger and Heidelberg Pharma. Insitro is listed as an emerging player.
Does 9Bio Therapeutics have an API?
No public API is recorded for 9Bio Therapeutics.
What industry is 9Bio Therapeutics in?
9Bio Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.